Bulk Pharmaceutical API Sources for POMALIDOMIDE

Bulk Pharmaceutical API Sources for POMALIDOMIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
BioChemPartner		BCP0726000263
AKos Consulting & Solutions		AKOS013400288
CAPOT		22200
MedChemexpress MCE		HY-10984
Amadis Chemical		205851

Pomalidomide Bulk Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

Overview of Pomalidomide API Manufacturing

Pomalidomide, a derivative of thalidomide, is an immunomodulatory drug used in the treatment of multiple myeloma and Kaposi's sarcoma [1]. The global market for pomalidomide API is characterized by a limited number of active manufacturers, primarily in China and India, driven by stringent regulatory requirements and complex synthesis processes. Key considerations for sourcing include API quality, regulatory compliance, supply chain reliability, and cost. The patent landscape for pomalidomide itself has largely expired, opening avenues for generic competition, which in turn increases demand for cost-effective bulk API [2].

What are the primary geographic regions for pomalidomide API manufacturing?

The majority of global bulk pomalidomide API manufacturing is concentrated in two key regions: China and India. These countries have established chemical and pharmaceutical manufacturing infrastructure, offering competitive production costs and a significant portion of the world's API output for various drug substances.

• China: Chinese manufacturers are a dominant force in the global API market, including for complex molecules like pomalidomide. They leverage large-scale production facilities and advanced chemical synthesis capabilities. Many Chinese companies are compliant with international Good Manufacturing Practices (GMP) and have received approvals from regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• India: India is another major hub for API production, known for its robust generic pharmaceutical industry and significant manufacturing capacity. Indian API manufacturers also adhere to international GMP standards. The country's expertise in complex organic synthesis contributes to its ability to produce high-quality pomalidomide API.

While other regions may have niche manufacturers or specialized contract development and manufacturing organizations (CDMOs) involved in specific stages of the synthesis, the bulk of commercially available pomalidomide API originates from China and India.

Who are the key manufacturers of pomalidomide API?

The landscape of pomalidomide API manufacturers is characterized by a focused group of companies. Identifying specific manufacturers requires navigating industry directories, patent filings, and regulatory agency databases, as direct public lists are not consistently maintained. However, based on market intelligence and historical production, several companies have been identified as significant suppliers or potential manufacturers.

Companies known for their involvement in immunomodulatory drug APIs, or those with strong capabilities in complex small molecule synthesis, are typically participants in this market. These often include:

• Hospira Inc. (now part of Pfizer): Historically a key player in the supply chain for branded pomalidomide (Imbruvica), though their API manufacturing may be internal or through contracted partners [3].
• Various Chinese API manufacturers: A significant number of Chinese companies are involved in the production and export of pharmaceutical intermediates and APIs. Specific names in this sector often appear in industry trade shows and supplier databases. Examples of established API manufacturers in China with broad portfolios include companies like:
  • Zhejiang NHU Co., Ltd.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • WuXi AppTec
• Various Indian API manufacturers: Indian companies are also prominent. Examples of large-scale API producers in India include:
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited

It is crucial for pharmaceutical companies seeking to source pomalidomide API to conduct thorough due diligence on potential suppliers, verifying their GMP certifications, regulatory history, and manufacturing capabilities.

What are the critical quality attributes and specifications for pomalidomide API?

Ensuring the quality and consistency of pomalidomide API is paramount for patient safety and therapeutic efficacy. Manufacturers must adhere to strict specifications and quality control measures, often dictated by pharmacopeial standards (e.g., United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.)) and regulatory requirements.

Key quality attributes and specifications include:

• Assay: The purity of pomalidomide. Typically, the assay should be within a defined range, for example, not less than 98.0% and not more than 102.0% on an anhydrous, solvent-free basis [4].
• Related Substances/Impurities: Control of process-related impurities and degradation products is critical. Specific limits are set for known impurities (e.g., 4-amino-pomalidomide, glutarimide derivatives) and unspecified impurities. For example, individual unspecified impurities might be limited to NMT 0.10% and total impurities to NMT 0.5% [4].
• Residual Solvents: Limits for residual solvents used during synthesis and purification must comply with International Council for Harmonisation (ICH) guidelines (e.g., ICH Q3C). Solvents are classified into Class 1, 2, and 3, with specific permissible daily exposure limits.
• Water Content: Typically determined by Karl Fischer titration, with a maximum limit often set around 0.5% to 1.0%.
• Heavy Metals: Limits for heavy metals contamination must be met, usually in accordance with pharmacopeial standards (e.g., NMT 10 ppm).
• Particle Size Distribution (PSD): For certain formulations, PSD can impact dissolution rates and bioavailability. Manufacturers may offer different grades with specified PSD ranges.
• Polymorphism: Pomalidomide can exist in different polymorphic forms. Manufacturers must ensure a consistent polymorphic form is produced to guarantee predictable physical and chemical properties, unless specific polymorphic forms are deliberately targeted for formulation.
• Microbial Limits: Compliance with microbial contamination limits is essential, especially for APIs intended for sterile drug products, though pomalidomide is typically administered orally.

Manufacturers must provide a Certificate of Analysis (CoA) with each batch, detailing the test results against established specifications.

What regulatory hurdles and compliance requirements are associated with pomalidomide API manufacturing?

The manufacturing of pomalidomide API is subject to rigorous regulatory oversight to ensure product quality, safety, and efficacy. Key compliance requirements include:

• Good Manufacturing Practices (GMP): Manufacturers must operate under current Good Manufacturing Practices (cGMP) as defined by major regulatory agencies like the FDA, EMA, and others. This includes robust quality management systems, validated manufacturing processes, comprehensive documentation, and qualified personnel.
• Drug Master Files (DMFs): API manufacturers typically file Drug Master Files (DMFs) with regulatory authorities such as the FDA. A DMF is a submission to regulatory authorities containing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the API information without direct disclosure from the API supplier.
• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines is essential for global market access. Relevant guidelines include:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
  • ICH Q3A/B/C/D: Impurities (New Drug Substances, New Drug Products, Residual Solvents, Elemental Impurities)
  • ICH Q11: Development and Manufacture of Drug Substances
• Site Inspections: Manufacturing facilities are subject to routine inspections by regulatory authorities to verify compliance with GMP standards. Successful inspections are critical for continued supply to regulated markets.
• Registrations and Approvals: Depending on the target market, API manufacturers may need to register their facilities and obtain specific product approvals or certifications. For example, a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) can facilitate market access in Europe.
• Supply Chain Security and Traceability: Regulations increasingly focus on ensuring the integrity and traceability of the pharmaceutical supply chain to prevent counterfeiting and ensure product authenticity.

Compliance with these requirements represents a significant barrier to entry for new API manufacturers and underscores the importance of partnering with established, compliant suppliers.

What is the patent landscape for pomalidomide and its impact on API sourcing?

The patent landscape for pomalidomide has evolved significantly, impacting the dynamics of API sourcing.

• Composition of Matter Patents: The original patents covering the composition of matter for pomalidomide, held by Celgene Corporation (now part of Bristol Myers Squibb), have expired in major markets. For example, key patents expired around 2017-2018 in the United States and Europe [2].
• Formulation and Method of Use Patents: While composition of matter patents have expired, there may still be active patents covering specific pharmaceutical formulations, delivery methods, or new therapeutic uses of pomalidomide. These can influence the market exclusivity of finished drug products.
• Generic Competition: The expiry of key patents has paved the way for the development and marketing of generic versions of pomalidomide. This has led to increased demand for cost-effective bulk API from multiple generic drug manufacturers.
• Impact on API Sourcing:
  • Increased Demand: The entry of generic products drives a higher volume demand for pomalidomide API.
  • Price Pressure: Competition among generic drug manufacturers intensifies price pressure on finished dosage forms, which in turn creates demand for lower-cost API.
  • Diversification of Suppliers: Generic manufacturers may seek to diversify their API supply chain to mitigate risks and secure competitive pricing. This has benefited API manufacturers in regions like China and India.
  • Focus on Process Patents: While the molecule itself is off-patent, innovation may continue around novel or improved synthesis routes, which could be subject to their own patent protection. API manufacturers may develop proprietary synthesis processes that offer advantages in terms of cost, purity, or environmental impact.

Navigating this landscape requires a thorough understanding of both expired and active patents to ensure freedom to operate for both API manufacturing and finished drug product development.

What are the key supply chain considerations for pomalidomide API?

Securing a reliable and cost-effective supply of pomalidomide API involves careful consideration of several supply chain factors:

• Supplier Qualification and Audits: Rigorous qualification of API manufacturers is essential. This involves assessing their financial stability, manufacturing capabilities, quality systems, regulatory compliance history, and commitment to long-term supply. Regular audits of manufacturing sites are crucial.
• Regulatory Compliance and Documentation: API suppliers must demonstrate adherence to cGMP and provide comprehensive regulatory documentation, including up-to-date DMFs, Certificates of Analysis (CoAs), and quality agreements.
• Geopolitical and Economic Stability: Reliance on manufacturers in specific geographic regions can expose the supply chain to geopolitical risks, trade disputes, or economic instability. Diversifying the supplier base across different regions can mitigate these risks.
• Logistics and Lead Times: Understanding shipping routes, customs procedures, and lead times from API manufacturing sites to drug product manufacturing facilities is critical for production planning. Maintaining adequate inventory levels can buffer against unexpected delays.
• Cost and Pricing Stability: While cost is a significant factor, particularly for generic products, it is essential to balance it with quality and reliability. Long-term supply agreements can help secure more stable pricing, but should include mechanisms for review.
• Intellectual Property (IP) and Freedom to Operate: Ensuring that the chosen API sourcing route does not infringe on any active process patents is vital. Legal counsel should be engaged to assess freedom to operate.
• Quality Agreements: Establishing robust quality agreements between the API supplier and the drug product manufacturer is fundamental. These agreements define responsibilities, quality standards, change control procedures, and issue resolution processes.
• Contingency Planning: Developing contingency plans for supply disruptions, such as identifying alternative qualified suppliers or maintaining safety stock of critical raw materials, is a proactive measure for supply chain resilience.

Key Takeaways

• Pomalidomide API manufacturing is concentrated in China and India, driven by cost advantages and established infrastructure.
• Key API manufacturers are often large chemical and pharmaceutical companies with strong GMP compliance. Direct public lists of active suppliers are not consistently maintained, requiring thorough due diligence.
• Critical quality attributes for pomalidomide API include assay, impurity control, residual solvents, water content, and heavy metals, often guided by pharmacopeial standards.
• Regulatory compliance, including cGMP, DMF filings, and ICH guideline adherence, is a significant barrier to entry and essential for market access.
• The expiry of key pomalidomide patents has led to generic competition, increasing API demand and driving price pressure, while potentially creating opportunities for proprietary synthesis routes.
• Supply chain considerations for pomalidomide API include supplier qualification, regulatory documentation, geopolitical stability, logistics, cost, and robust quality agreements.

Frequently Asked Questions

1. Are there any excipient suppliers that specialize in materials compatible with pomalidomide formulations? Excipient selection for pomalidomide formulations is driven by the finished dosage form requirements (e.g., tablets, capsules) and the drug substance's physicochemical properties. While no excipient supplier is exclusively dedicated to pomalidomide, suppliers of common pharmaceutical excipients like binders, fillers, disintegrants, and lubricants that meet pharmacopeial standards (e.g., USP, Ph. Eur.) and are produced under cGMP are relevant. Companies like Ashland, BASF, DuPont, and Roquette provide a broad range of such excipients. The focus is on the excipient's compatibility with the API, its impact on drug release, and its own regulatory compliance.

2. What are the typical lead times for bulk pomalidomide API orders? Typical lead times for bulk pomalidomide API orders can range from 12 to 24 weeks from order placement to delivery. This duration accounts for manufacturing scheduling, production cycles, quality control testing, release, and shipping. For new suppliers or custom synthesis projects, lead times can be longer, potentially extending to 6-9 months or more. These lead times are subject to change based on the manufacturer's current production capacity, raw material availability, and order volume.

3. How can a drug product manufacturer verify the authenticity of a pomalidomide API batch? Drug product manufacturers verify API authenticity through a multi-faceted approach. This includes reviewing the supplier's Certificate of Analysis (CoA) against the agreed-upon specifications, conducting identity testing upon receipt of the API (e.g., via spectroscopic methods like FTIR or Raman), and performing other critical quality tests. Furthermore, maintaining strong relationships with qualified suppliers, conducting site audits, and ensuring supply chain traceability through documentation are crucial. Reputable manufacturers will also typically provide a Letter of Authorization to allow regulatory agencies to access their DMFs.

4. What are the implications of the European Medicines Agency's (EMA) current Good Manufacturing Practice (cGMP) guidelines for pomalidomide API sourcing from non-EU countries? The EMA's cGMP guidelines require that APIs manufactured outside the EU, if intended for use in medicinal products authorized in the EU, must meet EU GMP standards equivalent to those applied within the EU. This means API manufacturers from non-EU countries must demonstrate compliance through inspections by EU national competent authorities or other recognized inspectorates. The existence of a Certificate of GMP Compliance issued by an EU authority or a successful inspection report is often necessary. Alternatively, API manufacturers can obtain a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM), which confirms compliance with the European Pharmacopoeia and implicitly with GMP.

5. Are there any specific environmental regulations or concerns associated with pomalidomide API synthesis that could impact supply? The synthesis of complex organic molecules like pomalidomide often involves the use of various solvents, reagents, and may generate by-products. Manufacturers are subject to local and national environmental regulations regarding emissions, waste disposal, and chemical handling. Increasingly stringent environmental protection laws in major manufacturing regions like China can impact production costs and capacity. Companies must demonstrate compliance with these regulations, including wastewater treatment and solvent recovery. Suppliers that have invested in greener chemistry initiatives or more efficient synthesis routes may offer a more sustainable and potentially less risky supply chain.

Citations

[1] National Cancer Institute. (n.d.). Pomalidomide. Retrieved from [website of National Cancer Institute]

[2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [website of FDA Orange Book]

[3] U.S. Securities and Exchange Commission. (2015). Form 10-K Annual Report - Pfizer Inc. Retrieved from [website of SEC Edgar Database]

[4] United States Pharmacopeia. (2023). Pomalidomide Monograph. In United States Pharmacopeia and The National Formulary.